Why Spinal Cords Don’t Heal and What One Biotech Is Doing About It

The spinal cord is roughly as thick as a finger, yet it carries almost every message between the brain and the rest of the body. When it is damaged, those messages can be cut off. The result is often paralysis below the injury, plus problems with things like bladder control and breathing. 

About 302,000 people in the U.S. live with a spinal cord injury, with estimates ranging between 255,000 and 383,000. About 18,400 new cases occur each year. Researchers point out that no approved therapy yet restores lost movement and feeling. 

So why does the spinal cord not heal the way skin does? Much of the answer lies in the body’s own response. Within days, cells gather at the injury site and build what scientists call a glial scar. At first, the scar is useful because it seals off the wound and limits further harm. The problem is that it stays, becoming a lasting barrier nerve fibers cannot cross. 

The scar contains sticky molecules called chondroitin sulfate proteoglycans, or CSPGs. Jerry Silver, a neuroscientist at Case Western Reserve University, has studied them for decades, describing nerve fibers reaching the scar and getting trapped, much like a fly on flypaper. In 2009, his lab helped identify a receptor called PTP sigma that nerve fibers use to sense CSPGs. That finding pointed to a new idea: instead of trying to remove the scar, block the signal that tells nerves to stop growing. 

That idea led to NVG-291, a drug that grew out of Silver’s work. It is a peptide, given as a daily injection under the skin, designed to counteract the blocking effect of CSPGs. Because it targets chemistry rather than the original wound, it is being tested in people injured years ago. In a Phase 1b/2a study called CONNECT SCI, participants with chronic injuries showed gains in hand function, nerve signaling, and quality of life. Earlier this month, the FDA granted the drug Breakthrough Therapy designation, which is meant to speed development but does not guarantee approval. 

The company behind the drug, NervGen Pharma Corp. (NASDAQ: NGEN), today named Sam Jackson, MD, MBA, as its Chief Medical Officer. He will work with the chief executive and the board to shape and carry out its clinical development strategy. 

At a biotech with no product on the market, this is one of the most important jobs in the building. The chief medical officer decides how trials are designed, who takes part, and what gets measured. A sound scientific idea can still fail if the trial built to test it is poorly planned.

Jackson has run many of those trials in brain and nerve diseases. He joins from Aditum Bio, where he was chief medical officer for neuroscience. At Neuron23, he designed the first global Phase 2 Parkinson’s disease trial to pair a companion diagnostic with a digital primary endpoint. At Alector, Inc. (NASDAQ: ALEC), he was interim chief medical officer and led a pivotal Phase 3 trial in frontotemporal dementia. Earlier, at Dynavax Technologies, he was clinical lead for an 8,500 patient Phase 3 hepatitis B vaccine trial and helped prepare the submission that won FDA approval. 

His first big test is RESTORE, a Phase 3 study expected to enroll about 150 adults in the U.S. and Canada who were injured between one and ten years ago. Half will receive NVG-291 and half a placebo for 12 weeks, with hand function as the main measure. NervGen expects results in the first half of 2028 and plans to ask the FDA for a meeting about ways to move faster. 

None of this changes what the biology will ultimately show. What a seasoned medical chief can do is make sure the question about that stubborn scar gets asked cleanly, so the answer is one that patients and regulators can trust.

Related posts

Subscribe to Newsletter